Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | Highlights for melanoma at SITC 2021

Diwakar Davar • 13 Nov 2021
SITC 2021
Melanoma Antibodies CMP-001 Pembrolizumab

Diwakar Davar, MD, University of Pittsburgh, Pittsburgh, PA, discusses the highlights of SITC 2021 for melanoma, including the final results of the Checkmate Pharmaceuticals trial (NCT02680184) investigating CMP-001 either alone or in combination with pembrolizumab. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

More from Diwakar Davar

5:57
Modified HSV1 for skin cancer treatment
Diwakar Davar • 2 Nov 2023
4:44
AMBER: anti-TIM3 antibody reverses T-cell exhaustion in NSCLC
Diwakar Davar • 2 Nov 2023
4:26
Novel delivery of TLR7/8 agonists for treatment of metastatic solid tumors
Diwakar Davar • 2 Nov 2023
3:45
PERIO: novel SD-101 treatment of uveal melanoma
Diwakar Davar • 2 Nov 2023

Related Videos

1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
2:12
Novel immunotherapeutic approaches to treat patients with melanoma
Christoffer Gebhardt • 9 Apr 2024
1:22
INTerpath-001: individualized neoantigen vaccines with pembrolizumab in melanoma
Christoffer Gebhardt • 9 Apr 2024
2:15
Reducing the need for sentinel node biopsies in cutaneous melanoma
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals